Eli Lilly and Novo Nordisk Compete Over Next-Phase Obesity Drug Innovations
The competition between Eli Lilly (LLY) and Novo Nordisk (NVO) in the obesity drug market is shifting from injectable GLP-1 drugs to oral treatments, higher-dose formulations, and next-generation therapies. Investors are now evaluating which company has a stronger long-term position as both firms develop new products beyond current blockbuster offerings. Novo Nordisk's Wegovy pill remains central to its growth strategy, with over 5 million U.S. prescriptions in six months and maintaining around 60% market share for new patient prescriptions. However, Novo faces challenges including declining gross margins and cost-cutting measures such as workforce reductions aimed at saving DKK 8 billion. Eli Lilly is leveraging its strong financial performance—48% year-over-year revenue growth in Q2—to fund the next generation of obesity drugs. Its two leading products, Mounjaro and Zepbound, contributed $15 billion to total revenues.
Topics: Eli Lilly GLP-1 drugs Novo Nordisk obesity market Wegovy Zepbound